Antibiotic Use in Suspected and Confirmed COVID-19 Patients Admitted to Health Facilities in Sierra Leone in 2020-2021: Practice Does Not Follow Policy.
AWaRe classification
COVID-19
SORT IT
Sierra Leone
antibiotic use
antimicrobial resistance
antimicrobial stewardship
operational research
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
28 03 2022
28 03 2022
Historique:
received:
11
02
2022
revised:
24
03
2022
accepted:
24
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
14
4
2022
Statut:
epublish
Résumé
Inappropriate use of antibiotics during the COVID-19 pandemic has the potential to increase the burden of antimicrobial resistance. In this study, we report on the prevalence of antibiotic use and its associated factors among suspected and confirmed COVID-19 patients admitted to 35 health facilities in Sierra Leone from March 2020-March 2021. This was a cross-sectional study using routinely collected patient data. Of 700 confirmed COVID-19 patients, 47% received antibiotics. The majority (73%) of the antibiotics belonged to the 'WATCH' group of antibiotics, which are highly toxic and prone to resistance. The most frequently prescribed antibiotics were azithromycin, ceftriaxone, amoxicillin, metronidazole, and amoxicillin-clavulanic acid. Antibiotic use was significantly higher in patients aged 25-34 years than in those with severe disease. Of 755 suspected COVID-19 patients, 61% received antibiotics, of which the majority (58%) belonged to the 'WATCH' category. The most frequently prescribed antibiotics were ceftriaxone, metronidazole, azithromycin, ciprofloxacin, and amoxycillin. The prevalence of antibiotic use among suspected and confirmed COVID-19 patients admitted to healthcare facilities in Sierra Leone was high and not in line with national and WHO case management guidelines. Training of health care providers, strengthening of antimicrobial stewardship programs, and microbiological laboratory capacity are urgently needed.
Identifiants
pubmed: 35409687
pii: ijerph19074005
doi: 10.3390/ijerph19074005
pmc: PMC8998021
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Metronidazole
140QMO216E
Ceftriaxone
75J73V1629
Azithromycin
83905-01-5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Références
Infect Prev Pract. 2021 Jun;3(2):100134
pubmed: 34316576
JAC Antimicrob Resist. 2020 Sep;2(3):dlaa048
pubmed: 32974610
Drug Saf. 2020 Jun;43(6):595-606
pubmed: 32166617
Clin Microbiol Infect. 2021 Apr;27(4):520-531
pubmed: 33418017
S Afr Med J. 2021 Apr 15;111(6):575-581
pubmed: 34382570
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
Int J Surg. 2020 Jun;78:185-193
pubmed: 32305533
Ups J Med Sci. 2016 Aug;121(3):159-64
pubmed: 27416324
Risk Manag Healthc Policy. 2020 Nov 10;13:2525-2534
pubmed: 33204193
BMJ. 2020 Apr 27;369:m1557
pubmed: 32341002
Lancet. 2020 Oct 10;396(10257):1050-1053
pubmed: 33007218
J Glob Antimicrob Resist. 2021 Mar;24:45-47
pubmed: 33307276
J Pharm Pract. 2021 Jul 22;:8971900211030248
pubmed: 34291681
Trop Med Health. 2021 Jun 23;49(1):51
pubmed: 34162445
PLoS One. 2021 May 11;16(5):e0251340
pubmed: 33974637
J Crit Care. 2020 Jun;57:279-283
pubmed: 32173110
World J Emerg Surg. 2016 Jul 15;11:33
pubmed: 27429642
Medicine (Baltimore). 2019 May;98(22):e15914
pubmed: 31145355
J Infect. 2020 Dec;81(6):952-960
pubmed: 32987097
Lancet Infect Dis. 2015 Oct;15(10):1203-1210
pubmed: 26164481
BMJ. 2020 May 18;369:m1983
pubmed: 32423901
BMC Infect Dis. 2019 Aug 27;19(1):746
pubmed: 31455256
J Infect. 2020 Aug;81(2):266-275
pubmed: 32473235
Clin Infect Dis. 2016 Dec 15;63(12):1639-1644
pubmed: 27682070
Lancet Glob Health. 2019 Jul;7(7):e861-e871
pubmed: 31200888
Glob Health Action. 2017;10(1):1287334
pubmed: 28462635
J Epidemiol Glob Health. 2015 Jun;5(2):143-50
pubmed: 25922323
Curr Pharm Biotechnol. 2019;20(8):643-652
pubmed: 30961489
J Antimicrob Chemother. 2017 Dec 01;72(12):3490-3495
pubmed: 28961983
Arch Public Health. 2017 Sep 14;75:54
pubmed: 28924475
BMJ Open Respir Res. 2020 Sep;7(1):
pubmed: 32900781
BMC Infect Dis. 2020 Jan 30;20(1):86
pubmed: 32000722
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812
J Pharm Policy Pract. 2019 Jul 17;12:20
pubmed: 31346472